ONCOLOGY / BASIC RESEARCH
 
KEYWORDS
TOPICS
ABSTRACT
Introduction:
Over the years, microRNAs (miRs) have been shown to exhibit therapeutic implications in the treatment of cancer. Consistently, this study was designed to examine the expression profile and to decipher the therapeutic implications of miR-939 in human liver cancer.

Material and methods:
Expression profiling was performed by qRT-PCR and the proliferation rate of liver cancer cells was monitored by Cell Counting Kit 8 (CCK8) and clonogenic assays. 4,6-diamidino-2-phenylindole (DAPI) staining and annexin V-FITC assays were used to determine the induction of apoptosis. Ultrastructural analysis was performed by transmission electron microscopy (TEM). Western blotting was used to determine protein expression.

Results:
miR-939 was found to be significantly (p < 0.05) downregulated in the liver cancerous tissues and cell lines. miR-939 overexpression significantly (p < 0.05) decreased the proliferation and colony formation of liver cancer cells. Ultrastructural analysis, DAPI and annexin V/PI assays showed induction of apoptosis in miR-939 overexpressing liver cancer cells. This was accompanied by upregulation of Bax, p53 and suppression of Bcl-2. In silico analysis showed CRKL to be the target of miR-939. The down regulation of CRKL mimicked the molecular effects of miR-939 in liver cancer cells. Nonetheless, CRKL overexpression abolished the growth inhibitory effects of miR-939 on liver cancer cells.

Conclusions:
The present study established the role of the miR-939/CRKL molecular axis in regulation of liver cancer proliferation, and it may also prove an essential therapeutic target for its management.
REFERENCES (26)
1.
Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2018; 68: 394-424.
 
2.
Thorgeirsson SS. Hepatic stem cells in liver regeneration. FASEB J 1996; 10: 1249-56.
 
3.
Wong MC, Jiang JY, Goggins WB, et al. International incidence and mortality trends of liver cancer: a global profile. Sci Rep 2017; 7: 45846.
 
4.
Koneru B, Cassavilla A, Bowman J, Iwatsuki S, Starzl TE. Liver transplantation for malignant tumors. Gastroenterol Clin North Am 1988; 17: 177.
 
5.
Urruticoechea A, Alemany R, Balart J, Villanueva A, Viñals F, Capella G. Recent advances in cancer therapy: an overview. Curr Pharm Design 2010; 16: 3-10.
 
6.
Angrand PO, Vennin C, Le Bourhis X, Adriaenssens E. The role of long non-coding RNAs in genome formatting and expression. Front Genet 2015; 6: 165.
 
7.
Naqvi AR, Sarwat M, Hasan S, Roychodhury N. Biogenesis, functions and fate of plant microRNAs. J Cell Physiol 2012; 227: 3163-8.
 
8.
Zeng Y. Principles of micro-RNA production and maturation. Oncogene 2006; 25: 6156.
 
9.
Wen KC, Sung PL, Yen MS, Chuang CM, Liou WS, Wang PH. MicroRNAs regulate several functions of normal tissues and malignancies. Taiwan J Obstet Gynecol 2013; 52: 465-9.
 
10.
Iorio MV, Croce CM. MicroRNAs in cancer: small molecules with a huge impact. J Clin Oncol 2009; 27: 5848-56.
 
11.
Muresan M, Zaharie F, Bojan A, et al. MicroRNAs in liver malignancies. Basic science applied in surgery. J BUON 2015; 20: 361-75.
 
12.
Ying X, Li-ya Q, Feng Z, Yin W, Ji-hong L. MiR-939 promotes the proliferation of human ovarian cancer cells by repressing APC2 expression. Biomed Pharmacother 2015; 71: 64-9.
 
13.
Zhang JX, Xu Y, Gao Y, et al. Decreased expression of miR-939 contributes to chemoresistance and metastasis of gastric cancer via dysregulation of SLC34A2 and Raf/MEK/ERK pathway. Mol Cancer 2017; 16: 18.
 
14.
Xi Y, Shalgi R, Fodstad O, Pilpel Y, Ju J. Differentially regulated micro-RNAs and actively translated messenger RNA transcripts by tumor suppressor p53 in colon cancer. Clin Cancer Res 2006; 12: 2014-24.
 
15.
Yoshino H, Seki N, Itesako T, Chiyomaru T, Nakagawa M, Enokida H. Aberrant expression of microRNAs in bladder cancer. Nat Rev Urol 2013; 10: 396-404.
 
16.
Iorio MV, Ferracin M, Liu CG, et al. MicroRNA gene expression deregulation in human breast cancer. Cancer Res 2005; 65: 7065-70.
 
17.
Hui A, How C, Ito E, Liu FF. Micro-RNAs as diagnostic or prognostic markers in human epithelial malignancies. BMC Cancer 2011; 11: 500.
 
18.
Libório-Kimura TN, Jung HM, Chan EK. miR-494 represses HOXA10 expression and inhibits cell proliferation in oral cancer. Oral Oncol 2015; 51: 151-7.
 
19.
Wada R, Akiyama Y, Hashimoto Y, Fukamachi H, Yuasa Y. miR-212 is downregulated and suppresses methyl-CpG-binding protein MeCP2 in human gastric cancer. Int J Cancer 2010; 127: 1106-14.
 
20.
Yu XF, Zou J, Bao ZJ, Dong J. miR-93 suppresses proliferation and colony formation of human colon cancer stem cells. World J Gastroenterol 2011; 17: 4711.
 
21.
Zhang H, Bao J, Zhao S, Huo Z, Li B. MicroRNA-490-3p suppresses hepatocellular carcinoma cell proliferation and migration by targeting the aurora kinase A gene (AURKA). Arch Med Sci 2020; 16: 395-406.
 
22.
Fornari F, Ferracin M, Trerè D, et al. Circulating micro-RNAs, miR-939, miR-595, miR-519d and miR-494, identify cirrhotic patients with HCC. PLoS One 2015; 10: e0141448.
 
23.
Chen G, Du C, Shen Z, et al. MicroRNA-939 inhibits cell proliferation via targeting LRSAM1 in Hirschsprung’s disease. Aging 2017; 9: 2471-9.
 
24.
Haldar S, Negrini M, Monne M, Sabbioni S, Croce CM. Downregulation of bcl-2 by p53 in breast cancer cells. Cancer Res 1994; 54: 2095-7.
 
25.
Hu XL, Olsson T, Johansson IM, Brännström T, Wester P. Dynamic changes of the anti- and pro-apoptotic proteins Bcl-w, Bcl-2, and Bax with Smac/Diablo mitochondrial release after photothrombotic ring stroke in rats. Eur J Neurosci 2004; 20: 1177-88.
 
26.
Wang Y, Dong QZ, Fu L, Stoecker M, Wang E, Wang EH. Overexpression of CRKL correlates with poor prognosis and cell proliferation in non-small cell lung cancer. Mol Carcinogen 2013; 52: 890-9.
 
eISSN:1896-9151
ISSN:1734-1922
Journals System - logo
Scroll to top